Dianthus Therapeutics DNTH Income Statement
| Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | ||
|---|---|---|---|---|---|---|
| —— | $396K+105% | $193K-83.4% | $1.16M-12.3% | $1.33M-39.0% | ||
| $34.53M+6.3% | $32.49M+23.8% | $26.25M-2.8% | $27M-13.5% | $31.21M+22.2% | ||
| $12.47M+52.1% | $8.2M-7.6% | $8.87M+20.9% | $7.34M+7.4% | $6.83M+4.6% | ||
| $47M+15.5% | $40.68M+15.8% | $35.12M+2.3% | $34.34M+3.3% | $33.24M+3.6% | ||
| -$46.53M-15.5% | -$40.29M-15.3% | -$34.93M-5.3% | -$33.18M-4.0% | -$31.92M-6.7% | ||
| $5.7M+61.8% | $3.52M+6.8% | $3.3M-10.0% | $3.67M+5.5% | $3.48M-26.4% | ||
| -$40.83M-11.1% | -$36.77M-16.2% | -$31.63M-7.2% | -$29.51M-3.8% | -$28.44M-13.0% | ||
| -$0.85+12.4% | -$0.97-10.2% | -$0.88-7.3% | -$0.820.0% | -$0.82-10.8% | ||
| -$46.5M-15.5% | -$40.26M-15.4% | -$34.9M-5.3% | -$33.15M-4.0% | -$31.89M-6.7% | ||
| -$46.53M-15.5% | -$40.29M-15.3% | -$34.93M-5.3% | -$33.18M-4.0% | -$31.92M-6.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Dianthus Therapeutics's income statement data come from?
- Every line is extracted from Dianthus Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.